Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotrokinra phase 3 study in moderately to severely active ulcerative colitis
NL-OMON60009Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in autoimmune colitis (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Clinical remission at Week I-12, Clinical remission at Week M-40 and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
icotrokinra
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON60009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60009.